U.S. markets close in 1 hour 38 minutes

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.94+0.79 (+9.74%)
As of 2:22PM EDT. Market open.

SELLAS Life Sciences Group, Inc.

Times Square Tower
Suite 2503 7 Times Square
New York, NY 10036
United States
646 200 5278

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, Pres, CEO & Director827.57kN/A1976
Ms. Barbara A. WoodExec. VP, Gen. Counsel & Sec.577.29kN/A1963
Dr. Dragan CicicSr. VP of Clinical Devel.435.43kN/A1963
Mr. John Thomas Burns CPA, CPAVP of Fin., Corp. Controller & Chief Accounting OfficerN/AN/A1985
Mr. Martin G. BaumChief Operating OfficerN/AN/A1966
Dr. Christopher R. ShackletonDirector of Clinical and Bus. OperationsN/AN/AN/A
Mr. Jörg W. BreitkopfHead of Clinical OperationsN/AN/AN/A
Mr. David D. MoserVP of Legal AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

Corporate Governance

SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.